(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.25%) $924.40
(0.36%) $0.935
(0.67%) $11.02
(0.14%) $0.800
(-0.07%) $92.11
0.24% HKD 20.95
Live Chart Being Loaded With Signals
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People's Republic of China and internationally...
Stats | |
---|---|
Dagens volum | 996 396 |
Gjennomsnittsvolum | 762 431 |
Markedsverdi | 52.05B |
EPS | HKD0.600 ( 2023-10-30 ) |
Last Dividend | HKD0.813 ( 2023-06-14 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 7.76 |
ATR14 | HKD0.0170 (0.08%) |
Volum Korrelasjon
Guangzhou Baiyunshan Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Guangzhou Baiyunshan Korrelasjon - Valuta/Råvare
Guangzhou Baiyunshan Økonomi
Annual | 2023 |
Omsetning: | HKD75.52B |
Bruttogevinst: | HKD14.19B (18.79 %) |
EPS: | HKD2.50 |
FY | 2023 |
Omsetning: | HKD75.52B |
Bruttogevinst: | HKD14.19B (18.79 %) |
EPS: | HKD2.50 |
FY | 2022 |
Omsetning: | HKD70.79B |
Bruttogevinst: | HKD13.28B (18.76 %) |
EPS: | HKD2.44 |
FY | 2021 |
Omsetning: | HKD69.01B |
Bruttogevinst: | HKD13.23B (19.17 %) |
EPS: | HKD2.29 |
Financial Reports:
No articles found.
Guangzhou Baiyunshan Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.813 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0300 | 2000-04-20 |
Last Dividend | HKD0.813 | 2023-06-14 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 25 | -- |
Total Paid Out | HKD6.04 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.35 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.80 | |
Div. Directional Score | 8.67 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
6033.HK | Ex Dividend Knight | 2023-09-19 | Semi-Annually | 0 | 0.00% | |
1818.HK | Ex Dividend Junior | 2023-06-07 | Annually | 0 | 0.00% | |
0848.HK | Ex Dividend Junior | 2023-05-24 | Annually | 0 | 0.00% | |
0006.HK | Ex Dividend Knight | 2023-08-30 | Semi-Annually | 0 | 0.00% | |
2588.HK | Ex Dividend Knight | 2023-09-25 | Semi-Annually | 0 | 0.00% | |
1382.HK | Ex Dividend Knight | 2023-08-15 | Semi-Annually | 0 | 0.00% | |
0455.HK | Ex Dividend Junior | 2023-06-29 | Annually | 0 | 0.00% | |
6823.HK | Ex Dividend Knight | 2023-08-17 | Semi-Annually | 0 | 0.00% | |
1931.HK | Ex Dividend Knight | 2023-09-04 | Semi-Annually | 0 | 0.00% | |
0966.HK | Ex Dividend Junior | 2023-07-10 | Sporadic | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0537 | 1.500 | 8.93 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0516 | 1.200 | 8.28 | 9.94 | [0 - 0.3] |
returnOnEquityTTM | 0.118 | 1.500 | 9.80 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.391 | -1.000 | 6.09 | -6.09 | [0 - 1] |
currentRatioTTM | 1.545 | 0.800 | 7.27 | 5.82 | [1 - 3] |
quickRatioTTM | 1.176 | 0.800 | 7.79 | 6.23 | [0.8 - 2.5] |
cashRatioTTM | 0.588 | 1.500 | 7.84 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.152 | -1.500 | 7.47 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 11.48 | 1.000 | 6.86 | 6.86 | [3 - 30] |
operatingCashFlowPerShareTTM | 5.44 | 2.00 | 8.19 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 4.44 | 2.00 | 7.78 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.342 | -1.500 | 8.63 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.188 | 1.000 | -0.202 | -0.202 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0678 | 1.000 | -0.644 | -0.644 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.741 | 1.000 | 7.00 | 7.00 | [0.2 - 2] |
assetTurnoverTTM | 0.961 | 0.800 | 6.93 | 5.54 | [0.5 - 2] |
Total Score | 11.53 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 7.77 | 1.000 | 9.32 | 0 | [1 - 100] |
returnOnEquityTTM | 0.118 | 2.50 | 9.87 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 4.44 | 2.00 | 8.52 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.19 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 5.44 | 2.00 | 8.19 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.391 | 1.500 | 6.09 | -6.09 | [0 - 1] |
pegRatioTTM | -0.968 | 1.500 | -9.79 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.117 | 1.000 | 9.57 | 0 | [0.1 - 0.5] |
Total Score | 5.80 |
Guangzhou Baiyunshan
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials in the People's Republic of China and internationally. The company operates through four segments: Great Southern TCM, Great Commerce, Great Health, and Others. It is also involved in the wholesale, retail, import, and export of Western and Chinese medicines, and medical apparatus and instruments; and research and development, production, and sale of beverages, food, healthcare products, pre-packaging food, dairy products, tablets, capsules, lozenges, injections, tortoise herb jelly, etc. In addition, the company invests in health industry, such as medical care, health management, health preservation, elderly care, etc.; and provides commercial and advertising services. As of December 31, 2021, it had 154 retail chain pharmacy outlets, which included 22 Cai Zhi Lin pharmacy outlets, 36 Jian Min pharmacy outlets, 51 GPC Prescription Pharmacy outlets, and 23 Hainan Guangyao Chenfei Pharmaceutical Chain Co., Ltd outlets, as well as 22 retail stores. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.